- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01012258
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects (CHANCE)
Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety of Cetuximab When Given in Combination With Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects
Primary objective: to assess the antitumor activity and safety profile of cetuximab when given in combination with radiotherapy (RT) for the treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN) in Chinese subjects.
Secondary objective: to assess the pharmacokinetic (PK) profile and immunogenicity of cetuximab in Chinese subjects.
Further objective: to identify for cetuximab potential predictive biomarkers of response and safety.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
Changsha, Hunan, China
- Xiangya Hospital of Central South University
-
Guangzhou, China
- Sun Yat-sen University Cancer Center
-
Hangzhou, China
- Zhejiang Provincial Cancer Hospital
-
Shanghai, China
- Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
-
Wuhan, Hubei, China
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
Wuhan, Hubei, China
- Zhongnan Hospital of Wuhan University
-
-
Fujian
-
Fuzhou, Fujian, China
- Fujian Provincial Tumor Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Inpatient greater than or equal to (>=) 18 years of age
- Pathologically proven squamous cell carcinoma arising in the oropharynx, hypopharynx or larynx
- Stage III or IV disease with an expected survival of at least 12 months
- Medically suitable to withstand a course of concomitant boost RT
- Presence of at least 1 bi-dimensionally measurable lesion identified either by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to modified World Health Organization (WHO) criteria
- Karnofsky Performance Status (KPS) >=80 at trial entry
- Neutrophils >=1.5*10^9/Liter (L), platelet count >= 100*10^9/L, hemoglobin >= 90 gram/liter (g/L)
- Total bilirubin less than or equal to (<=) 2*upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3*ULN
- Serum creatinine <=133 micromole/liter (mcmol/L)
- Serum calcium within normal range
- Effective contraception if procreative potential exists (applicable to both male and female subjects)
- Chinese with Chinese citizenship
- Signed written informed consent
Exclusion Criteria:
- Evidence of distant metastatic disease
- Squamous cell carcinoma arising in the nasopharynx or oral cavity
- Receipt of prior systemic chemotherapy within the last 3 years
- Previous surgery for the tumor under study other than biopsy
- Receipt of prior RT to the head and neck
- Currently receiving RT as part of a postoperative regimen following primary surgical resection
- Planned neck dissection after trial RT
- Active infection (infection requiring IV antibiotics), including active tuberculosis, or known and declared human immunodeficiency virus (HIV)
- Uncontrolled diabetes mellitus, pulmonary fibrosis, acute pulmonary disorder, interstitial pneumonia, cardiac failure or liver failure
- Uncontrolled hypertension defined as systolic blood pressure >=180 millimeter of mercury (mmHg) and/or diastolic blood pressure >=130 mmHg under resting conditions
- Pregnancy (absence to be confirmed by serum beta human chorionic gonadotrophin [beta-HCG] test) or breastfeeding
- Concomitant chronic systemic immune therapy or hormonal therapy as cancer therapy
- Other concomitant anticancer therapies
- Documented or symptomatic brain or leptomeningeal metastasis
- Clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled cardiac insufficiency
- Previous treatment with monoclonal antibody therapy, other signal transduction inhibitors or epidermal growth factor receptor (EGFR) targeting therapy
- Evidence of previous other malignancy within the last 5 years
- Intake of any investigational medication within 30 days before trial entry
- Other protocol-defined exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cetuximab
All eligible subjects will receive cetuximab treatment only during week 1 of the treatment course and concomitant cetuximab and boost radiotherapy (RT) during week two to week seven of the treatment course
|
Cetuximab 400 milligram/square meter (mg/m^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Overall Response (BOR)
Time Frame: Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 3 months following the 8 weeks after the end of RT visit until the end of trial (EOT) visit
|
Best overall (objective) response was defined as the occurrence of complete response (CR) or partial response (PR) based on the investigator's assessment according to modified World Health Organization (WHO) criteria confirmed at a repeat assessment performed no less than 28 days after the criteria for response were first met.
CR was defined as disappearance of all index lesions.
PR was defined as a 50% or more decrease in the sum of the products of diameters (SOPD) of index lesions compared to the baseline SOPD, with no evidence of PD.
|
Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 3 months following the 8 weeks after the end of RT visit until the end of trial (EOT) visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: Baseline up to disease progression or withdrawal or 12 weeks after the last radiotherapy of the last participant
|
Progression-free survival was defined as the duration (in months) from first administration of trial treatment to first observation of PD (radiological or clinical, if radiological PD is not available), or death due to any cause.
The PFS time of participants without observation of PD but death occurring after two or more missed consecutive tumor assessments (i.e.
two-fold scheduled time interval of two consecutive tumor assessments) was censored on the date of last tumor assessment or first administration of trial treatment (whichever was later).
|
Baseline up to disease progression or withdrawal or 12 weeks after the last radiotherapy of the last participant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Li Gao, Radiotherapy Department, Cancer Institute & Hospital, Chinese Academy of Medical Science, Beijing, China
- Study Director: Junliang Cai, Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd., an Affiliate of Merck KGaA, Darmstadt, Germany
- Principal Investigator: Guozhen Xu, Radiotherapy Department, Cancer Institute & Hospital, Chinese Academy of Medical Science, Beijing, China
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EMR62241-054
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma of the Head and Neck
-
National Cancer Institute (NCI)Not yet recruitingStage II Squamous Cell Carcinoma of the Head and Neck | Stage III Squamous Cell Carcinoma of the Head and Neck | Stage IV Squamous Cell Carcinoma of the Head and NeckUnited States
-
Bristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Washington University School of MedicineCelgene CorporationActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and NeckUnited States
-
Arnaud Bewley, MDNational Cancer Institute (NCI); Genentech, Inc.TerminatedStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage...United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Hi-Q Marine Biotech International, Ltd.RecruitingSquamous Cell Carcinomas of the Head and NeckTaiwan
-
Queensland HealthMerck Sharp & Dohme LLCRecruitingHead and Neck Cancer | Cutaneous Squamous Cell Carcinoma of the Head and NeckAustralia
-
Vanderbilt-Ingram Cancer CenterBoehringer Ingelheim; National Comprehensive Cancer NetworkWithdrawnSquamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head or Neck | Metastatic Squamous Cell Carcinoma of the Head or Neck
Clinical Trials on Cetuximab + concomitant boost radiotherapy
-
National Cancer Institute, EgyptUnknownRadiotherapy Side EffectEgypt
-
Gustave Roussy, Cancer Campus, Grand ParisMinistry of Health, FranceCompleted
-
Groupe Oncologie Radiotherapie Tete et CouCompleted
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedBreast Cancer | Radiation Toxicity
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedHead and Neck CancerUnited States, Canada
-
St George Hospital, AustraliaUnknown
-
Instituto Nacional de Cancerologia, ColumbiaCompletedUterine Cervical Neoplasms
-
University College, LondonNational Institute for Health Research, United KingdomUnknownEarly Breast CancerFrance, Korea, Republic of, United Kingdom, Italy, United States, China, Malaysia, Saudi Arabia, South Africa, Spain, Switzerland, Thailand
-
University of ChicagoBristol-Myers SquibbCompletedHead and Neck CancerUnited States
-
The Greater Poland Cancer CentreCompletedProstate CancerPoland